{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:29:16Z","timestamp":1787761756121,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Keratoconjunctivitis is one of the most common pathologies worldwide, caused by several infectious and noninfectious factors. This study aimed to determine the effect of povidone-iodine 2% eye drops in treating adenoviral keratoconjunctivitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      This analytic cross-sectional study was conducted on patients referred to Farabi Eye Hospital Records of patients with adenoviral keratoconjunctivitis, more than 12 years of age, and no allergy to iodine who were treated by povidone-iodine 2% eye drops four times a day were assessed. Data included demographic characteristics, family history of adenoviral keratoconjunctivitis, follicular conjunctivitis, petechial conjunctival hemorrhages, periauricular lymphadenopathy, and the presence of conjunctival pseudomembrane were collected from the records. Discharge decrease, injection decrease, swelling decrease, pseudomembrane formation, periauricular lymphadenopathy, and subepithelial infiltration on the 7\n                      <jats:sup>th<\/jats:sup>\n                      day of assessment by physical examination were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Patients with a mean (\u00b1standard deviation) age of 33.77 (11.01) years were assessed. At the baseline, 95 (99.0%) follicular conjunctivitis, 94 (97.9%) petechial conjunctival hemorrhages, 29 (30.2%) periauricular lymphadenopathy, and 5 (5.2%) conjunctival pseudomembrane were recorded. On the 7\n                      <jats:sup>th<\/jats:sup>\n                      day of treatment, the discharge decreased in 92.7% of patients, and the injection decreased in 90.6%. The swelling decrease was also detected in 79.2% of patients. Subepithelial infiltration was only seen in 21.9% of the study population. Results showed that 2.1% of patients had periauricular lymphadenopathy, and only 13 out of 96 patients (13.5%) had pseudomembrane formation after 7 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Based on the safety, availability, and tolerability of povidone-iodine and its promising effects on patients with adenoviral keratoconjunctivitis, further clinical trials assessing the impact of this drug in a longer duration of follow-up can be recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ojo.ojo_180_22","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T02:50:51Z","timestamp":1676947851000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The effect of povidone-iodine 2% eye drops in the treatment of adenoviral keratoconjunctivitis"],"prefix":"10.4103","volume":"16","author":[{"given":"Mohammad","family":"Soleimani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ali","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Esfandiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Soleymanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afagh Hassanzadeh","family":"Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20240908","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1185\/03007990903038269","article-title":"Acute conjunctivitis: Truth and misconceptions","volume":"25","author":"O'Brien","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R2-15-20240908","first-page":"182","article-title":"The incidence of adenoviruses in viral conjunctivitis","volume":"50","author":"Torres Rojas","year":"1998","journal-title":"Rev Cubana Med Trop"},{"key":"R3-15-20240908","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.optm.2006.11.012","article-title":"The prevalence of adenoviral conjunctivitis at the wills eye hospital emergency room","volume":"78","author":"Sambursky","year":"2007","journal-title":"Optometry"},{"key":"R4-15-20240908","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21859\/isv.3.2.7","article-title":"Incidence of adenoviral conjunctivitis in patients referred to the Iran University affiliated hospital","volume":"3","author":"Shamsi","year":"2009","journal-title":"Iran J Virol"},{"key":"R5-15-20240908","first-page":"2029","article-title":"Determination of prevalence, sensitivity and specificity of clinical signs and symptoms of adenoviral keratoconjunctivitis","volume":"30","author":"Mokhtari","year":"2013","journal-title":"J Isfahan Med Sch"},{"key":"R6-15-20240908","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/OPTO.S217722","article-title":"Epidemiology and molecular diagnosis of acute conjunctivitis in patients attending Hamadan, West Iran ophthalmology clinics 2016-2017","volume":"11","author":"Johari Moghadam","year":"2019","journal-title":"Clin Optom (Auckl"},{"key":"R7-15-20240908","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s40135-019-00207-y","article-title":"Adenoviral keratoconjunctivitis: diagnosis, management, and prevention","volume":"7","author":"Kuo","year":"2019","journal-title":"Current Ophthalmology Reports"},{"key":"R8-15-20240908","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ico.0000170693.13326.fb","article-title":"Adenoviral keratoconjunctivitis in a tertiary care eye clinic","volume":"25","author":"Butt","year":"2006","journal-title":"Cornea"},{"key":"R9-15-20240908","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s40135-019-00207-y","article-title":"Adenoviral keratoconjunctivitis: Diagnosis, management, and prevention","volume":"7","author":"Kuo","year":"2019","journal-title":"Curr Ophthalmol Rep"},{"key":"R11-15-20240908","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.eye.6700330","article-title":"Epidemic kerato-conjunctivitis \u2013 Do outbreaks have to be epidemic?","volume":"17","author":"Cheung","year":"2003","journal-title":"Eye (Lond"},{"key":"R12-15-20240908","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/cxo.12544","article-title":"Infection control guidelines for optometrists 2016","volume":"100","author":"Lian","year":"2017","journal-title":"Clin Exp Optom"},{"key":"R13-15-20240908","first-page":"493","article-title":"New paradigms in infectious eye disease: Adenoviral keratoconjunctivitis","volume":"81","author":"Rajaiya","year":"2006","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R14-15-20240908","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0161-6420(00)00177-9","article-title":"A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis","volume":"107","author":"Shiuey","year":"2000","journal-title":"Ophthalmology"},{"key":"R15-15-20240908","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/archopht.119.10.1487","article-title":"Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: A controlled clinical pilot study","volume":"119","author":"Hillenkamp","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R16-15-20240908","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0161-6420(02)00992-2","article-title":"The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: A controlled clinical pilot study","volume":"109","author":"Hillenkamp","year":"2002","journal-title":"Ophthalmology"},{"key":"R17-15-20240908","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1167\/iovs.10-5944","article-title":"Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis","volume":"52","author":"Clement","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-15-20240908","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000246027","article-title":"Inactivation of human viruses by povidone-iodine in comparison with other antiseptics","volume":"195","author":"Kawana","year":"1997","journal-title":"Dermatology"},{"key":"R19-15-20240908","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1600-0420.2005.00414.x","article-title":"Reduction of conjunctival bacterial flora by povidone-iodine, ofloxacin and chlorhexidine in an outpatient setting","volume":"83","author":"Barkana","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"R20-15-20240908","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2006-926633","article-title":"Povidone-iodine for treatment of adenoviral conjunctivitis: An in vitro study","volume":"223","author":"Monnerat","year":"2006","journal-title":"Klin Monbl Augenheilkd"},{"key":"R21-15-20240908","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/15569527.2014.888077","article-title":"Povidone iodine in the treatment of adenoviral conjunctivitis in infants","volume":"34","author":"\u00d6zen Tunay","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"R22-15-20240908","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12325-009-0062-1","article-title":"A combination povidone-iodine 0.4%\/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis","volume":"26","author":"Pelletier","year":"2009","journal-title":"Adv Ther"},{"key":"R23-15-20240908","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41433-020-1023-9","article-title":"Open globe injuries in children under 7 years referred to a tertiary center in Iran from 2006 to 2016","volume":"35","author":"Tabatabaei","year":"2021","journal-title":"Eye (Lond"},{"key":"R24-15-20240908","first-page":"9","article-title":"Povidone-iodine in ophthalmic surgery","volume":"1","author":"Hale","year":"1970","journal-title":"Ophthalmic Surg"},{"key":"R25-15-20240908","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1755-3768.1982.tb00627.x","article-title":"Assessment of possible toxic effects of polyvinylpyrrolidone-iodine upon the human eye in conjunction with cataract extraction An endothelial specular microscope study","volume":"60","author":"Wille","year":"1982","journal-title":"Acta Ophthalmol (Copenh"},{"key":"R26-15-20240908","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/ICO.0000000000000682","article-title":"Safety of intracameral injection of minimal bactericidal concentration of povidone iodine on the corneal endothelium in a rabbit model","volume":"35","author":"ElKitkat","year":"2016","journal-title":"Cornea"},{"key":"R27-15-20240908","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jtos.2019.08.005","article-title":"Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The reducing adenoviral patient infected days (RAPID) study","volume":"17","author":"Shorter","year":"2019","journal-title":"Ocul Surf"},{"key":"R28-15-20240908","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jop.2011.0082","article-title":"Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: A pilot study","volume":"28","author":"Trinavarat","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R30-15-20240908","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/jop.2018.0122","article-title":"The in vitro evaluation of povidone-iodine against multiple ocular adenoviral types","volume":"35","author":"Yates","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"R31-15-20240908","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3109\/02713683.2014.964419","article-title":"Dexamethasone\/povidone eye drops versus artificial tears for treatment of presumed viral conjunctivitis: A randomized clinical trial","volume":"40","author":"Pinto","year":"2015","journal-title":"Curr Eye Res"},{"key":"R32-15-20240908","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41433-020-01344-6","article-title":"Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: A prospective randomized controlled study","volume":"36","author":"Ricciardelli","year":"2022","journal-title":"Eye (Lond"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_180_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:05:01Z","timestamp":1787760301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_180_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_180_22","relation":{},"ISSN":["0974-620X"],"issn-type":[{"value":"0974-620X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}